Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKurt, Bulent
dc.contributor.authorYalcin, Serap
dc.contributor.authorAlagoz, Engin
dc.contributor.authorKarslioglu, Yildirim
dc.contributor.authorYigit, Nuri
dc.contributor.authorGunal, Armagan
dc.contributor.authorDeveci, M. Salih
dc.date.accessioned2019-11-24T20:58:13Z
dc.date.available2019-11-24T20:58:13Z
dc.date.issued2012
dc.identifier.issn1046-3976
dc.identifier.issn1559-0097
dc.identifier.urihttps://dx.doi.org/10.1007/s12022-012-9218-7
dc.identifier.urihttps://hdl.handle.net/20.500.12513/3021
dc.descriptionWOS: 000307518400001en_US
dc.descriptionPubMed ID: 22767446en_US
dc.description.abstractIt has been shown that BRAF(V600E) mutation in papillary thyroid carcinomas (PTC) is associated both with pathogenesis and poor prognosis. In this study, we aimed to investigate the relationship of the BRAF(V600E) mutation and the established prognostic factors in a cohort of Turkish patients with PTC. Forty-six cases of papillary thyroid carcinoma have been evaluated for the presence of BRAF(V600E) mutation. BRAF(V600E) has been examined by restriction fragment length polymorphism. BRAF(V600E) mutation status has been compared with well-known histopathological and clinical prognostic parameters such as invasion of thyroid capsule, extrathyroidal extension, and the presence of lymph node and/or distant metastasis. We have found that BRAF(V600E) mutation was present in the majority of our cases (40/46). Considering the stage of the disease, five of the negative cases were in stage 1 while the remaining one was in stage 2. Only one BRAF(V600E) negative case has shown extrathyroidal extension and lymph node metastasis. All four patients with distant metastasis had BRAF(V600E) mutation. Statistical analyses revealed that there are no significant relationship between the BRAF(V600E) mutation and the established prognostic factors. We found a relatively higher BRAF(V600E) mutation rate in classical type PTC than in other similar studies. We think that the limited number of our cases may either weaken or mask some potentially important relationship between BRAF(V600E) mutation and the established prognostic factors.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [19816]en_US
dc.description.sponsorshipThe authors would like to thank to Scientific and Technological Research Council of Turkey (TUBITAK) for their support (Grant No: 19816). We also would like to express our sincere appreciation to FAVOR (FMF Arthritis Vasculitis and Orphan Diseases Research) laboratories at Gulhane Military Medical Academy, Institute of Health Sciences for their supports in conducting the experiments and invaluable guidance for the preparation of the manuscript.en_US
dc.language.isoengen_US
dc.publisherHUMANA PRESS INCen_US
dc.relation.isversionof10.1007/s12022-012-9218-7en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPapillary thyroid carcinomaen_US
dc.subjectBRAF(V600E)en_US
dc.subjectPrognosisen_US
dc.subjectDiagnosisen_US
dc.titleThe Relationship of the BRAF(V600E) Mutation and the Established Prognostic Factors in Papillary Thyroid Carcinomasen_US
dc.typearticleen_US
dc.relation.journalENDOCRINE PATHOLOGYen_US
dc.contributor.departmentKırşehir Ahi Evran Üniversitesi, Kaman Meslek Yüksekokuluen_US
dc.identifier.volume23en_US
dc.identifier.issue3en_US
dc.identifier.startpage135en_US
dc.identifier.endpage140en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster